Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycythemia Vera 1

Interventions

pembrolizumab 95 Specimen Handling 79 Magnetic Resonance Spectroscopy 70 Carboplatin 59 Cisplatin 56 Biopsy 56 Nivolumab 51 Radiotherapy 47 Cyclophosphamide 44 Paclitaxel 43 Radiation 36 durvalumab 33 Gemcitabine 31 olaparib 30 Dexamethasone 30 Etoposide 29 Doxorubicin 28 atezolizumab 26 Taxes 25 Rituximab 25 Docetaxel 25 Ipilimumab 24 Bevacizumab 24 Vincristine 23 Lenalidomide 23 Pemetrexed 22 Cytarabine 22 X-Rays 21 Radiotherapy, Intensity-Modulated 21 Prednisone 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × bomedemstat × 90 days × Clear all

NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed

20 enrolled 19 charts

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡